The study by Dingli and colleagues65 demonstrated that MV-NIS could induce significant tumour regression in KAS6/1 myeloma xenografts, as well as in MV-resistant MM1 tumours when combined with I131 radiotherapy. Here, SLC5A5 is linked to neoplasm.